Last €53.57 EUR
Change Today -0.16 / -0.30%
Volume 2.7K
BRM On Other Exchanges
Symbol
Exchange
New York
Mexico
Sao Paulo
Frankfurt
As of 3:16 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BRM) Snapshot

Open
€54.02
Previous Close
€53.73
Day High
€54.46
Day Low
€53.51
52 Week High
01/27/15 - €56.09
52 Week Low
06/10/14 - €34.12
Market Cap
88.9B
Average Volume 10 Days
3.3K
EPS TTM
--
Shares Outstanding
1.7B
EX-Date
12/30/14
P/E TM
--
Dividend
€1.38
Dividend Yield
2.08%
Current Stock Chart for BRISTOL-MYERS SQUIBB CO (BRM)

bristol-myers squibb co (BRM) Details

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company’s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliance with OliPass Corporation to discover and develop therapeutics against various targets using OliPass' technology platform. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Founded in 1887

bristol-myers squibb co (BRM) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: $1.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $901.1K
Chief Operating Officer and Director
Total Annual Compensation: $748.3K
Executive Vice President, General Counsel and...
Total Annual Compensation: $843.1K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $736.1K
Compensation as of Fiscal Year 2013.

bristol-myers squibb co (BRM) Key Developments

Celldex Therapeutics, Inc. and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo in Advanced Refractory Solid Tumors

Celldex Therapeutics, Inc. and Bristol Myers-Squibb announced the initiation of a Phase 1/2 dose escalation and cohort expansion study examining the investigational combination of varlilumab, Celldex's CD27 targeting investigational immune-activating antibody and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab). The study will be conducted in adult patients with advanced non-small cell lung cancer (NSCLC), metastatic melanoma (MEL), colorectal cancer (CRC), ovarian cancer, and head and neck squamous cell carcinoma (SCCHN). Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody that binds to the PD-1 receptor expressed on activated T-cells. This study will evaluate the safety and tolerability of the combination and address the hypothesis that the combination of these two mechanisms enhance the anti-tumor activity compared to either agent alone. Celldex is responsible for conducting the study and development costs will be shared. The Phase 1 dose-escalation portion of the study will assess the safety and tolerability of varlilumab at doses ranging from 0.1 to 10 mg/kg when administered with Opdivo (3mg/kg). Following dose escalation, a Phase 2 portion of the study will include 5 disease specific cohorts, with either 18 (CRC, SCCHN, ovarian) or 35 (NSCLC and MEL) patients in each cohort. Patients will be treated with varlilumab until intolerance, disease progression or completion of up to 4 cycles. There is no limit on the duration of treatment with Opdivo. The primary objective of the Phase 2 study is overall response rate. Secondary objectives include pharmacokinetics assessments, determining the immunogenicity of varlilumab when given in combination with Opdivo and further assessing the anti-tumor activity of combination treatment, including duration of response, time to response, progression-free survival and overall survival.

FDA Approves Bristol-Myers' Evotaz for Treatment of HIV-1 Infection in Adults

Bristol-Myers Squibb Co. announced that the U.S. Food and Drug Administration has approved Evotaz tablets in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. Evotaz is coformulated to be one pill, once-daily, combining the protease inhibitor atazanavir, which is marketed as Reyataz capsules, and cobicistat, a pharmacokinetic enhancer marketed by Gilead Sciences Inc. (GILD). The use of Evotaz in patients who have previously received HIV medication should be guided by their baseline resistance to protease inhibitors. Evotaz and Reyataz do not cure HIV-1 infection or AIDS. Evotaz is the first and only protease inhibitor pharmacoenhanced by cobicistat that is supported by comparative Phase III trial data.

Bristol-Myers Squibb Company Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year of 2015

Bristol-Myers Squibb Company reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, total revenues were $4,258 million against $4,441 million a year ago. Loss before income taxes was $60 million against earnings before income taxes of $869 million a year ago. Net earnings attributable to the company were $13 million against $726 million a year ago. Diluted earnings per common share were $0.01 against $0.44 a year ago. Net earnings used for Diluted EPS calculation – Non-GAAP was $771 million against $842 million a year ago. Diluted earnings per share — Non-GAAP was $0.46 against $0.51 a year ago. For the full year, total revenues were $15,879 million against $16,385 million a year ago. Earnings before income taxes were $2,381 million against $2,891 million a year ago. Net earnings attributable to the company were $2,004 million against $2,563 million a year ago. Diluted earnings per common share were $1.20 against $1.54 a year ago. Net earnings used for Diluted EPS calculation – Non-GAAP was $3,085 million against $3,019 million a year ago. Diluted earnings per share — Non-GAAP was $1.85 against $1.82 a year ago. For the full year of 2015, the company is setting its 2015 GAAP and non-GAAP EPS guidance range at $1.55 - $1.70. Both GAAP and non-GAAP guidance assume current exchange rates. Key 2015 non-GAAP guidance assumptions include: Worldwide revenues between $14.4 billion and $15.0 billion. Full-year gross margin as a percentage of revenues of approximately 74%. The financial guidance for 2015 excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified. The non-GAAP 2015 guidance also excludes other specified items as discussed under Use of Non-GAAP Financial Information. Details reconciling adjusted non-GAAP amounts with the amounts reflecting specified items are provided in supplemental materials available on the company’s website.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BRM:GR €53.57 EUR -0.16

BRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $60.35 USD -2.77
Amgen Inc $152.26 USD -4.11
Biogen Idec Inc $389.16 USD +35.91
Eli Lilly & Co $72.00 USD -0.11
Novo Nordisk A/S kr295.50 DKK -4.40
View Industry Companies
 

Industry Analysis

BRM

Industry Average

Valuation BRM Industry Range
Price/Earnings 50.2x
Price/Sales 6.3x
Price/Book 6.6x
Price/Cash Flow 49.9x
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit www.bms.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.